A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
Type of Study: Clinical Trial
Sponsor / Support: EORTC, Bayer
Primary Objectives: The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone
Design: This is a randomized phase III open label trial.
Sample Size: 560 patients
Principal Investigator: Andrey Soares (Steering Committee – LACOG)
Countries LATAM: Brazil

Ongoing studies
Breast
GBECAM 0115 – AMAZONA III
LACOG 0115 – LORELEI
LACOG 0413 – Male Breast Cancer
LACOG 0615 – LATINABreast
LACOG 2118 – ALEXANDRA/IMpassion 030
PALLAS
Gastro-Intestinal
LACOG/GTG 1318 – CCA
LACOG 0119
Gynecological
LACOG 0215 – EVITA
LACOG 1018 – PALBO in Ovarian Cancer
Genitourinary
LACOG 1518 – Bladder Cancer Registry
LACOG 0515 – Testicular Registry
LACOG 0217 – IRONMAN
LACOG 1818 – Prostate Cancer Registry
LACOG 0218 – Hercules
LACOG 0415 – APA in Prostate Cancer
LACOG 0519 – PEACE III
Lung
LACOG 0116 – LATINO LUNG
LACOG 0118 – RELANCE
LACOG 0417 – CNS MTX
LACOG 1918
LACOG 0718 – PCI Project
LACOG 2218 – PACIFIC BRAZIL
Neuro
LACOG 0619